Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 5.83 mg/ml - injection, solution - excipient ingredients: poloxamer; sodium hydroxide; sucrose; citric acid; phenol; water for injections - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 10 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).

Australia - English - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide; sodium chloride - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections; citric acid monohydrate - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

global harvest pharmaceuticals pty ltd - metaraminol tartrate, quantity: 19 mg (equivalent: metaraminol, qty 10 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

global harvest pharmaceuticals pty ltd - metaraminol tartrate, quantity: 9.5 mg (equivalent: metaraminol, qty 5 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

global harvest pharmaceuticals pty ltd - metaraminol tartrate, quantity: 5.7 mg (equivalent: metaraminol, qty 3 mg) - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - evening primrose oil - cutaneous cream - 200mg/1gram